We are very pleased that Hamburg News is featuring us as a company and our AI-solution for breast cancer diagnostics

We invite you to join our VP Sales & Marketing, Dr. Anil Berger, as speaker on this year’s Annual Meeting of the Japanese Society of Digital Pathology on Friday August 20th 2021, 15:00-16:00 JST. He will present data from our study on the robustness of our flagship AI-product BreastIHC against real-life image variability.

We invite you to join our CEO, Felix Faber, as one of the Keynote Speakers at the 8th Emirates Pathology and Digital Pathology Conference online on August 11th at 10:55 a.m. BST.

Sectra has just expanded their AI marketplace with digital pathology and we are very excited to be included. As of now our CE-marked breast cancer diagnostic tool BreastIHC is a part of the Sectra Amplfier Store https://lnkd.in/d8u9wmG.

We are proud to inform you that our product BreastIHC is now CE-IVD cleared! This makes Mindpeak the first company to have approval for Deep Learning-driven IHC quantification of the proliferation markers Ki-67, Estrogen and Progesterone in breast tumor that can distinguish tumorous and non-tumorous cells in single-stained IHC slides. BreastIHC is a plug-and-play software that works across most stainers and scanners without parameterization or retraining. This is an enormously important step in our company's short history of only 3 years!

Mindpeak’s CTO Dr. Tobias Lang and Dr. med. Holger Hauspurg describe the future of cancer diagnostics in an article for the magazine Journal Oncology.